Clinical Trials & Translational Studies in Scleroderma & PAH

For general information on studies, or if you are not sure which one is suitable, contact Nina Kishore at 617.414.2509 or nkishore@bu.edu

Actively Recruiting Clinical Trials

Study Name

Indication

Principal Investigator

Study Contact

Email/Phone

The Scleroderma Clinical Repository SSc Robert Lafyatis, MD Eric Stratton eas@bu.edu

617.414.2507

Rilonacept– Randomized, Double-Blind,
Placebo-Controlled Trial of IL1-TRAP –
A Phase I/II Biomarker Trial
Diffuse SSc Robert Lafyatis, MD Jessica Ziemek jziemek@bu.edu

617.638.5383

Quantification of Septal Thickening in
Scleroderma Patients Utilizing Hyperpolarized
129Xe MRI
SSc with ILD Robert Lafyatis, MD Fei-Ying Cheong fycheong@bu.edu

617.638.4344

A Randomized, Double-Blind, Placebo-
Controlled, Phase II Multi-Center Trial of a
Monoclonal Antibody to CD20 (Rituxamab)
For the Treatment of Systemic Sclerosis-
Associated Pulmonary Arterial Hypertension
Harrison Farber, MD

Robert Simms, MD

Eric Stratton

Fei-Ying Cheong

eas@bu.edu
ASK1 – A Phase 2, Dose-Ranging, Randomized, Double-Blind, Placebo Controlled Study of GS-4997 in Subjects with Pulmonary Arterial Hypertension PAH Harrison Farber, MD Kim Finch kimtobin@bu.edu

617.638.4475

MOTION- A Phase IV, Prospective, Single-Arm, Open-Label Study to Measure Outcomes in Patients with Pulmonary Arterial Hypertension not on Active Treatment PAH Harrison Farber, MD Kim Finch kimtobin@bu.edu

617.638.4475

MELODY-1 Study – A prospective, multicenter, double-blind, randomized, placebo-controlled, parallel-group, 12-week study to evaluate the safety and tolerability of macitentan in subjects with combined pre- and post-capillary pulmonary hypertension (CpcPH) due to left ventricular dysfunction. PH Harrison Farber, MD Fei-Ying Cheong fycheong@bu.edu

617.638.4344

LARIAT – A dose-ranging study of the efficacy and safety of Bardoxolone Methyl in patients with PAH PAH Harrison Farber, MD Kim Finch kimtobin@bu.edu

617.638.4475

ARENA – A Randomized, Double-blind, Parallel-group, Placebo-controlled Phase 2 Trial of APD811, an Oral IP Receptor Agonist, in Patients with Pulmonary Arterial Hypertension PAH Harrison Farber, MD Fei-Ying Cheong fycheong@bu.edu

617.638.4344

Actively Recruiting Translational Studies

Fibroblast and Immune Cell
Culture From Skin
Diffuse SSc Robert Lafyatis, MD Jessica Ziemek jziemek@bu.edu

617.638.5383

CORT Biomarker Study SSc Robert Lafyatis, MD Eric Stratton eas@bu.edu

 

 

 

BU_SclerodermaLogoFnl_SMALL